0647 GMT - Regulatory approvals for UltraGreen.ai's fluorescence imaging system in new markets lays the groundwork for future Asia-Pacific expansion, says DBS Group Research's Amanda Tan in a note. The approvals strengthen Ultragreen's ability to work with healthcare institutions and distribution partners, the analyst notes. However, not all required components, such as the dye needed for surgeries, have been approved, and she doesn't expect the healthcare-technology company to immediately enter these markets. Its Asia-Pacific revenue therefore isn't likely to be materially accretive in the near term, with earnings uplift likely to be progressive, she says. DBS maintains its buy rating and US$2.00 target price. Shares rise 0.65% to US$1.55. (megan.cheah@wsj.com)
(END) Dow Jones Newswires
March 13, 2026 02:47 ET (06:47 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.